At Integra LifeSciences, we are driven by our purpose of restoring patients' lives. We innovate treatment pathways to advance patient outcomes and set new standards of surgical, neurologic, and regenerative care. We offer a comprehensive portfolio of high quality, leadership medical technology brands. For the latest news and information about Integra and its products, please visit www.integralife.com. Since receiving the third-party audit findings for its Boston, Massachusetts, manufacturing facility in Mar ...

A month has gone by since the last earnings report for Integra LifeSciences (IART) . Shares have added about 26% in that time frame, outperforming the S&P 500. Will the recent positive trend continue leading up to its next earnings release, or is Integra due for a pullback? Before we dive into how investors and analysts have reacted as of late, let's take a quick look at the most recent earnings report in order to get a better handle on the important catalysts. Integra's Q1 Earnings Match Estimates, Margins ...

Investors in Integra LifeScience Holdings Corporation (IART) need to pay close attention to the stock based on moves in the options market lately. That is because the Jun 21, 2024 $40.00 Call had some of the highest implied volatility of all equity options today. What is Implied Volatility? Implied volatility shows how much movement the market is expecting in the future. Options with high levels of implied volatility suggest that investors in the underlying stocks are expecting a big move in one direction o ...

Have you evaluated the performance of Integra LifeSciences' (IART) international operations during the quarter that concluded in March 2024? Considering the extensive worldwide presence of this medical device maker, analyzing the patterns in international revenues is crucial for understanding its financial resilience and potential for growth. The global economy today is deeply interlinked, making a company's engagement with international markets a critical factor in determining its financial success and gro ...

Integra LifeSciences Holdings Corporation (IART) delivered adjusted earnings per share (EPS) of 55 cents in the first quarter of 2024, down 25.7% year over year. The metric was in line with the Zacks Consensus Estimate.The adjustment excludes the impact of certain non-recurring charges like structural optimization charges, the Boston recall and EU Medical Device Regulation charges.GAAP loss per share in the first quarter was 4 cents against GAAP EPS of 29 cents in the year-ago quarter.Revenue DiscussionTota ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES ☒ EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2024 or TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES ☐ EXCHANGE ACT OF 1934 For the transition period from to COMMISSION FILE NUMBER 000-26224 INTEGRA LIFESCIENCES HOLDINGS CORPORATION (EXACT NAME OF REGISTRANT AS SPECIFIED IN ITS CHARTER) Delaware 51-0317849 (STAT ...

Integra LifeSciences Holdings Corporation [IART] Q1 2024 Earnings Conference Call May 6, 2024 8:30 AM ET Company Participants Jan De Witte - President & CEO Lea Knight - CFO Chris Ward - IR Conference Call Participants Vik Chopra - Wells Fargo Steve Lichtman - Oppenheimer Kristen Stewart - C.L. King & Associates Robbie Marcus - J.P. Morgan Matt Taylor - Jefferies Ryan Zimmerman - BTIG Joanne Wuensch - Citigroup Richard Newitter - Truist Securities Craig Bijou - Bank of America Securities Jayson Bedford - Ra ...

Integra LifeSciences (IART) reported $368.87 million in revenue for the quarter ended March 2024, representing a year-over-year decline of 3.2%. EPS of $0.55 for the same period compares to $0.74 a year ago.The reported revenue compares to the Zacks Consensus Estimate of $362.14 million, representing a surprise of +1.86%. The company has not delivered EPS surprise, with the consensus EPS estimate being $0.55.While investors closely watch year-over-year changes in headline numbers -- revenue and earnings -- ...

| --- | --- | --- | --- | --- | --- | --- | |----------------------------------------------------------|-------------------|----------------|--------------|-------------------------------------|-------------------------|----------------------------| | Summary Balance Sheet ($M) \nCash and Cash Equivalents | 12/31/23 \n$276 | 3/31/24 \n$592 | FCF Capex | Operating Cash Flow, Free Cash Flow | ($M) 300 \n$246.3 250 | & Adj. FCF Conversion (%) | | Short-term Investments | $33 | $71 | | | $46.7 200 | | | Total D ...

News Release Integra LifeSciences Reports First Quarter 2024 Financial Results PRINCETON, N.J., May 6, 2024 - Integra LifeSciences Holdings Corporation (NASDAQ: IART), a leading global medical technology company, today reported financial results for the first quarter ending March 31, 2024. First Quarter 2024 Highlights • First quarter revenues of $368.9 million declined 3.1% on a reported basis and declined 2.5% on an organic basis compared to the prior year. Revenue increased 1.6% on an organic basis exclu ...